A practical reference on obesity research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-14 and is reviewed periodically as new material appears.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
chemical decomposition The breakdown of a single particle or entity (such as a molecule or reactive intermediate) into two or more fragments, or a chemical reaction in which two or more products are formed from a single reactant. Contrast chemical synthesis.
For services to Further Education and Skills Michael Davidson. Volunteer and Trustee, Royal Ulster Constabulary George Cross Foundation. For Voluntary Service. Janet Ann Davies. Councillor, Denbighshire County Council. For services to Local Government, to the NHS and to the community in Rhuddlan, Denbighshire. Jean Carol Davies. Chair and Coach, Saints Netball Club, Truro. For services to Netball and to the community in Cornwall. Dr Robert Havard Davies. Doctor, Neuro-Development Team, Betsi Cadwaladr University Health Board. For services to the NHS. Francisco Domingo Davila Davila. For services to the community in Wymondham, Norfolk. Brendan William Davis. Head of Operations, Government Car Service. For services to Government and Major Events. Rachel Frances Davis. For services to the community in Cranford, Northamptonshire. Audrey Dempsey. Founder, Glasgow's No1 Baby and Family Support Service. For services to Families and Vulnerable People in Glasgow. Janet Mary Dicks. For services to the community in Hadleigh, Suffolk. Ann Doreen May Doody. For services to the community in Ilfracombe, Devon. Trevor Samuel John Douglas. General Manager, Belfast Cathedral. For services to Peacebuilding and to the community in Northern Ireland. Lee William Doyle. Chief Executive Officer, Brentford FC Community Sports Trust. For services to Sport and to the community in Brentford, London Borough of Hounslow. Janet Shirley Dyer. Catering Manager, National Fire Service College. For services to the community in Moreton-in-Marsh, Gloucestershire. Patricia Carol Earl.
=== Maximum depositional age === Some of the most important information we can get from detrital zircon ages is the maximum depositional age of the referring sedimentary unit. The sedimentary unit cannot be older than the youngest age of the analyzed detrital zircons because the zircon should have existed before the rock formation. This provides useful age information to rock strata where fossils are unavailable, such as the terrestrial successions during Precambrian or pre-Devonian times. Practically, maximum depositional age is averaged from a cluster of youngest age data or the peak in age probability because the youngest U-Pb age within a sample is almost always younger with uncertainty.
The serum total clearance of CPA is approximately 2.32 ± 0.38 mL/min/kg. Levels of CPA and 15β-OH-CPA with oral administration decrease biphasically over a period of 24 to 120 hours. The elimination of CPA appears to be biphasic. In one study, a peak at 3.4 hours post-dose with an initial half-life of 3.4 hours and later half-life of 1.6 days was observed following a single 50 mg oral dose of CPA. The high lipophilicity and fat storage of CPA may be the reason for its longer subsequent half-life.
Sources: en.wikipedia.org
Silica alumina gel - light yellow, chemically stable, flame-resistant, insoluble except in alkali or hydrofluoric acid. Superficial polarity, thermal stability, performance greater than fine-pored silica gel. Stabilizing silica gel - non-crystalline micro-porous solid powder, nontoxic, flame-resisting, used in brewery of grains for beer to improve taste, clearness, color, and foam and for removal of non-micro-organism impurities.
Photoacoustic Tomography (PAT) is a hybrid imaging modality that utilizes the photoacoustic effect without the use of ionizing radiation. It works without contact with very fast laser pulses that generate ultrasound in the tissue under examination. The local absorption of the light leads to sudden local heating and the resulting thermal expansion. The result is broadband acoustic waves. The original distribution of absorbed energy can be reconstructed by measuring the outgoing ultrasound waves with appropriate ultrasound transducers.
==== Organic molecules ==== A recent international project has developed and determined the hydrogen, carbon, and nitrogen isotopic composition of 19 organic isotopic reference materials, now available from USGS, IAEA, and Indiana University. These reference materials span a large range of δ2H (-210.8‰ to +397.0‰), δ13C (-40.81‰ to +0.49‰), and δ15N (-5.21‰ to +61.53‰), and are amenable to a wide range of analytical techniques. The organic reference materials include caffeine, glycine, n-hexadecane, icosanoic acid methyl ester (C20 FAME), L-valine, methylheptadecanoate, polyethylene foil, polyethylene power, vacuum oil, and NBS-22.
== Veterinary uses == Prednisolone is used in the treatment of inflammatory and allergic conditions in cats, dogs, horses, small mammals such as ferrets, birds, and reptiles. Its usage in treating inflammation, immune-mediated disease, Addison's disease, and neoplasia is often considered off-label use. Many drugs are commonly prescribed for off-label use in veterinary medicine." Studies in ruminating species, such as alpacas, have shown that oral administration of the drug is associated with a reduced bioavailability compared to intravenous administration; however, levels that are therapeutic in other species can be achieved with oral administration in alpacas. It is used in a broad spectrum of diseases, for example, inflammation of scleral tissues, cornea, and conjunctiva in dogs. In horses, prednisolone acetate suspensions are priorly used to treat inflammation in the middle layer of the eye, also known as anterior uveitis and equine recurrent uveitis (ERU), which is the leading cause of visual impairment in horses. Prednisolone acetate eye drops are not to be used in other animals such as birds. Prednisolone acetate eye drops are also prescribed to dogs and cats to lessen swelling, redness, burning, and pain sensations after surgeries of the eye. Cats with conjunctivitis usually are required to avoid using ophthalmic preparations of corticosteroids and its derivatives. The most typical infections are caused by herpes virus.
In contrast to cheddaring, making cheeses like Camembert requires a gentler treatment of the curd. It is carefully transferred to cheese hoops and the whey is allowed to drain from the curd by gravity, generally overnight. The cheese curds are then removed from the hoops to be brined by immersion in a saturated salt solution. The salt absorption stops bacteria growing, as with Cheddar. If white mould spores have not been added to the cheese milk it is applied to the cheese either by spraying the cheese with a suspension of mould spores in water or by immersing the cheese in a bath containing spores of, e.g., Penicillium candida. By taking the cheese through a series of maturation stages where temperature and relative humidity are carefully controlled, allowing the surface mould to grow and the mould-ripening of the cheese by fungi to occur. Mould-ripened cheeses ripen very quickly compared to hard cheeses (weeks against months or years). This is because the fungi used are biochemically very active when compared with starter bacteria. Some cheeses are surface-ripened by moulds, such as Camembert and Brie, some are ripened internally, such as Stilton, which is pierced with stainless steel wires, to admit air to promote mould spore germination and growth, as with Penicillium roqueforti. Surface ripening of some cheeses, such as Saint-Nectaire, may also be influenced by yeasts which contribute flavour and coat texture.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.